Anne co-founded 23andMe in 2006 after a decade spent in healthcare investing, focused primarily on biotechnology companies. Her hope was to empower consumers with access to their own genetic information and to create a way to generate more personalized information so that commercial and academic researchers could better understand and develop new drugs and diagnostics. Presently, 23andMe has built one of the world's largest databases of individual genetic information. Its novel, web-based research approach allows for the rapid recruitment of participants to many genome-wide association studies at once, reducing the time and money needed to make new discoveries, and the company has created a proven and standardized resource for finding new genetic association and confirming genetic loci discovered by others. Under Anne's leadership 23andMe has made significant advances in bringing personalized medicine directly to the public. Anne graduated from Yale University with a BS in Biology. Getting access to and understanding her own genetic information had always been one of her ambitions.
Sponsored · Whitepaper
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health SciencesFrom Our Editors · Podcast
Becoming the Cell & Gene Therapy Hub
Sponsored · Whitepaper
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
PRA Health Sciences© 2007-2022, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.